加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$162.79
−US$4.68 · -2.79%
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
前收盘价
US$162.79
−US$4.68 · -2.79%
盘后
US$163.25
+US$0.46 · +0.28%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
日内区间
当前US$162.79
52周区间
当前US$162.79
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
56
合理估值
情绪
62
看涨
风险
48
风险偏高
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
日内区间
当前US$162.79
52周区间
当前US$162.79
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 9.82亿 USD | 7.39亿 USD | 5.64亿 USD | 4.5亿 USD | 3.74亿 USD |
| 销货成本 | 3.49亿 USD | 2.9亿 USD | 2.27亿 USD | 1.56亿 USD | 1.23亿 USD |
| 毛利 | 6.33亿 USD | 4.49亿 USD | 3.37亿 USD | 2.93亿 USD | 2.51亿 USD |
| 研究与开发 | 3.64亿 USD | 3.48亿 USD | 3.67亿 USD | 3.74亿 USD | 2.63亿 USD |
| 销售、一般及管理费用 | 7.06亿 USD | 5.45亿 USD | 4.51亿 USD | 4.64亿 USD | 3.99亿 USD |
| 营业费用 | 10.7亿 USD | 8.93亿 USD | 9.02亿 USD | 8.38亿 USD | 6.62亿 USD |
| 利息收入 | 3409.5万 USD | 5369.1万 USD | 3536.5万 USD | 606.9万 USD | 393万 USD |
| 利息支出 | 389.7万 USD | 258.1万 USD | 257.8万 USD | 257.7万 USD | 257.7万 USD |
| 折旧和摊销 | 3973.6万 USD | 4238.7万 USD | 4288.1万 USD | 3596.2万 USD | 2227.1万 USD |
| 营业利润 | −4.37亿 USD | −4.44亿 USD | −5.65亿 USD | −5.44亿 USD | −4.11亿 USD |
| 净利润 | −4.16亿 USD | −4.36亿 USD | −4.79亿 USD | −6.55亿 USD | −4.06亿 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$202.4
上涨空间 24.33%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6.37亿0.03%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB4.61亿0.25%1853亿 USD0.03%US$288.16-0.46%
Vanguard Morningstar Small-Cap Growth ETFVBK2.65亿0.58%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF2.45亿0.25%954亿 USD0.05%US$233.52-0.63%
iShares Russell Mid-Cap Growth ETFIWP1.08亿0.54%200.95亿 USD0.23%US$140.99-1.47%
ARK Genomic Revolution ETFARKG9877.3万4.64%22.19亿 USD0.75%US$49.48-3.55%
iShares Russell Mid-Cap ETFIWR8989.07万0.16%567.65亿 USD0.18%US$109.47-0.32%
iShares Russell 1000 Growth ETFIWF7108.3万0.05%1305.08亿 USD0.18%US$127.13-0.61%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell Mid-Cap Growth ETFIWPARK Genomic Revolution ETFARKGiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
